prikaz prve stranice dokumenta Predklinička ispitivanja inhibicijskog i interakcijskog potencijala novih lijekova na razini citokroma P450
  Download
PDF 820.37 KB
Professional paper - Professional paper
Predklinička ispitivanja inhibicijskog i interakcijskog potencijala novih lijekova na razini citokroma P450
Farmaceutski glasnik, 71 (2015), 5; 229-242. urn:nbn:hr:163:107539
Bojić, Mirza

Institutional repository: Repository of Faculty of Pharmacy and Biochemistry University of Zagreb

Cite this document

Bojić, M. (2015). Predklinička ispitivanja inhibicijskog i interakcijskog potencijala novih lijekova na razini citokroma P450. Farmaceutski glasnik, 71. (5), 229-242. Retrieved from https://urn.nsk.hr/urn:nbn:hr:163:107539

Bojić, Mirza. "Predklinička ispitivanja inhibicijskog i interakcijskog potencijala novih lijekova na razini citokroma P450." Farmaceutski glasnik, vol. 71, no. 5, 2015, pp. 229-242. https://urn.nsk.hr/urn:nbn:hr:163:107539

Bojić, Mirza. "Predklinička ispitivanja inhibicijskog i interakcijskog potencijala novih lijekova na razini citokroma P450." Farmaceutski glasnik 71, no. 5 (2015): 229-242. https://urn.nsk.hr/urn:nbn:hr:163:107539

Bojić, M. (2015) 'Predklinička ispitivanja inhibicijskog i interakcijskog potencijala novih lijekova na razini citokroma P450', Farmaceutski glasnik, 71(5), pp. 229-242. Available at: https://urn.nsk.hr/urn:nbn:hr:163:107539 (Accessed 22 November 2024)

Bojić M. Predklinička ispitivanja inhibicijskog i interakcijskog potencijala novih lijekova na razini citokroma P450. Farmaceutski glasnik [Internet]. 2015 [cited 2024 November 22];71(5):229-242. Available at: https://urn.nsk.hr/urn:nbn:hr:163:107539

M. Bojić, "Predklinička ispitivanja inhibicijskog i interakcijskog potencijala novih lijekova na razini citokroma P450", Farmaceutski glasnik, vol. 71, no. 5, pp. 229-242, 2015. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:163:107539. [Accessed: 22 November 2024]

Metadata
Title (croatian)Predklinička ispitivanja inhibicijskog i interakcijskog potencijala novih lijekova na razini citokroma P450
AuthorMirza Bojić
Author's institutionUniversity of Zagreb
Faculty of Pharmacy and Biochemistry
(Department of medicinal chemistry)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Pharmacy
Pharmacy
Abstract (english)
In 1998 mibefradil - an antihypertensive drug, blocker of calcium channel, was withdrawn from the marked after more than 30 clinically significant interactions with other xenobiotics were reported in less than a year on the market. As in most cases enzyme involved was from the superfamily of cytochromes P4SO. In this paper approach in studying cytochromes P450 and drug inhibitions in vitro is reviewed. Different types of inhibition are described: direct and time dependent inhibition, and metabolism dependent inactivation. These studies were accepted by pharmaceutical industry for the assessment of potential drug-drug interactions in early stages of drug development, and now are being formalized by regulatory bodies in Europe (2013), Japan (2014) and USA to follow.
Keywords (croatian)
Languagecroatian
Publication typeProfessional paper - Professional paper
Publication statusPublished
Peer reviewPeer review - domestic
Publication versionPublished version
Journal titleFarmaceutski glasnik
Numberingvol. 71, no. 5, pp. 229-242
p-ISSN0014-8202
URN:NBNurn:nbn:hr:163:107539
Publication2015
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2020-10-02 09:38:03